AIM: In this study, we attempted to identify the possible antinociceptive and anti-inflammatory actions of the aqueous phase, the ethyl acetate phase and one unknown flavonoid obtained from aerial parts of Piptadenia stipulacea, known in Brazil as "jurema-branca", "carcará" and "rasga-beiço". MATERIALS AND METHODS: Aerial parts of Piptadenia stipulacea were used and after fractionation, the flavonoid FGAL was obtained. Experiments were conducted on Swiss mice using the acetic acid-induced writhing test, the hot plate test, the formalin-induced pain test and zymosan A-induced peritonitis test. RESULTS: The aqueous and ethyl acetate phases (p.o., 100mg/kg); and the flavonoid FGAL (p.o. and i.p. at 100 micromol/kg), reduced the nociception produced by acetic acid, by 49.92%, 54.62%, 38.97% and 64.79%, respectively. In vivo inhibition of nociception by the ethyl acetate phase (100mg/kg, p.o.) in the hot plate test was favorable, indicating that this fraction exhibited central activity. The ethyl acetate phase (100mg/kg, p.o.) reduced the formalin effects in both phases by 28.51% and 55.72%, respectively. Treatment with the aqueous phase (100mg/kg, p.o.) and FGAL (100 micromol/kg, i.p.) only protected the second phase by 69.76% and 68.78%, respectively. In addition, it was observed in the zymosan A-induced peritonitis test that the aqueous phase, the ethyl acetate phase and the FGAL exhibited anti-inflammatory activity, reducing significantly the number of recruit cells by 35.84%, 37.70% and FGAL (1), respectively. CONCLUSIONS: These data demonstrate that the FGAL elicits pronounced antinociceptive activity against several pain models. The actions of this flavonoid probably are due to antioxidative properties. However, pharmacological and chemical studies are continuing in order to characterize the mechanism(s) responsible for this antinociceptive action and also to identify other active substances present in Piptadenia stipulacea. Published by Elsevier Ireland Ltd.
AIM: In this study, we attempted to identify the possible antinociceptive and anti-inflammatory actions of the aqueous phase, the ethyl acetate phase and one unknown flavonoid obtained from aerial parts of Piptadenia stipulacea, known in Brazil as "jurema-branca", "carcará" and "rasga-beiço". MATERIALS AND METHODS: Aerial parts of Piptadenia stipulacea were used and after fractionation, the flavonoid FGAL was obtained. Experiments were conducted on Swiss mice using the acetic acid-induced writhing test, the hot plate test, the formalin-induced pain test and zymosan A-induced peritonitis test. RESULTS: The aqueous and ethyl acetate phases (p.o., 100mg/kg); and the flavonoid FGAL (p.o. and i.p. at 100 micromol/kg), reduced the nociception produced by acetic acid, by 49.92%, 54.62%, 38.97% and 64.79%, respectively. In vivo inhibition of nociception by the ethyl acetate phase (100mg/kg, p.o.) in the hot plate test was favorable, indicating that this fraction exhibited central activity. The ethyl acetate phase (100mg/kg, p.o.) reduced the formalin effects in both phases by 28.51% and 55.72%, respectively. Treatment with the aqueous phase (100mg/kg, p.o.) and FGAL (100 micromol/kg, i.p.) only protected the second phase by 69.76% and 68.78%, respectively. In addition, it was observed in the zymosan A-induced peritonitis test that the aqueous phase, the ethyl acetate phase and the FGAL exhibited anti-inflammatory activity, reducing significantly the number of recruit cells by 35.84%, 37.70% and FGAL (1), respectively. CONCLUSIONS: These data demonstrate that the FGAL elicits pronounced antinociceptive activity against several pain models. The actions of this flavonoid probably are due to antioxidative properties. However, pharmacological and chemical studies are continuing in order to characterize the mechanism(s) responsible for this antinociceptive action and also to identify other active substances present in Piptadenia stipulacea. Published by Elsevier Ireland Ltd.
Authors: Alessandra M V Ritter; Talita P Domiciano; Waldiceu A Verri; Ana Carla Zarpelon; Lorena G da Silva; Carmem P Barbosa; Maria Raquel M Natali; Roberto K N Cuman; Ciomar A Bersani-Amado Journal: Inflammopharmacology Date: 2012-10-09 Impact factor: 4.473
Authors: Juliane C Silva; Camila de S Araújo; Sarah Raquel G de Lima-Saraiva; Raimundo G de Oliveira-Junior; Tâmara C Diniz; Carlos Wagner de S Wanderley; Raimundo C Palheta-Júnior; Rosemairy L Mendes; Adriana G Guimarães; Lucindo J Quintans-Júnior; Jackson Roberto G da S Almeida Journal: BMC Complement Altern Med Date: 2015-06-24 Impact factor: 3.659
Authors: Cibério L Macêdo; Luiz H C Vasconcelos; Ana C C de Correia; Italo R R Martins; Daysianne P de Lira; Bárbara V de O Santos; Fabiana de A Cavalcante; Bagnólia A da Silva Journal: Molecules Date: 2014-11-27 Impact factor: 4.411
Authors: Juliana da Nóbrega Carreiro; Iara Leão Luna de Souza; Joedna Cavalcante Pereira; Luiz Henrique César Vasconcelos; Rafael de Almeida Travassos; Barbara Viviana de Oliveira Santos; Bagnólia Araújo da Silva Journal: BMC Complement Altern Med Date: 2017-12-02 Impact factor: 3.659